Capital One-Backed Atmosfy Launches 10% Cash Back on Travel and Experiences
SAN FRANCISCO--(BUSINESS WIRE)--Jun 4, 2025--
Atmosfy, the leading video platform for reviewing live dining, nightlife, and travel experiences, today announced the launch of the All-Access Pass by Atmosfy, an in-app rewards engine that markets travel, experiences and more. Following a recent investment from Capital One Ventures, the new rewards engine will continue the company's mission of powering the next generation of real-world discovery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604270684/en/
Atmosfy, the leading video platform for reviewing live dining, nightlife, and travel experiences, announces the launch of the All-Access Pass by Atmosfy, an in-app rewards engine that markets travel, experiences and more.
All-Access Pass features Expedia-powered hotel inventory and brand integrations across dining, nightlife, and experiences. Atmosfy users now earn 10% cash back on over 3.5 million global properties, plus access to curated perks from marquee partners, including Tock.
'As the go-to platform for Gen Z discovery, we're proud to partner with the world's largest travel brands like Capital One, Tock, and Expedia to unlock meaningful savings across hotels, restaurants, and experiences,' said Michael Ebel, Founder & CEO of Atmosfy. 'We're not just helping users find where to go, we're helping them save when they get there. Atmosfy is fueling global experiences, offering inspiration, connection, and rewards that help the next generation experience more of the world.'
To date, over 250 million experiences have been discovered on Atmosfy across 10,000 cities and 150 countries. As the leading video discovery platform for Gen Z travelers, Atmosfy is redefining how the next generation explores the world by favoring immersive, authentic video content over static reviews. Gen Z already contributes over $150 billion annually to the global travel market, and Atmosfy helps brands convert this high-intent audience at scale.
According to Atmosfy's latest State of the Market report, Gen Z's travel decisions are accelerating toward social-first, video-led platforms that blur the lines between inspiration and action. Users are three times more likely to make a purchase after watching video content, and 56% say they rely on friends and creators to guide real-world decisions. That behavior is translating into more spontaneous travel patterns – over 30% of Gen Z travelers now book flights less than a week in advance, and 44% make last-minute hotel bookings.
As planning cycles shrink, Atmosfy's All-Access Pass rewards real-time discovery with instant perks and builds long-term loyalty around the creators, content, and communities Gen Z trusts. With travel bookings on Atmosfy up 3x year-over-year in 2025, Gen Z increasingly prioritizes spontaneous and video-led decision-making. The platform expects this growth to accelerate through 2026 as more users unlock real-world savings and brands embrace performance-based campaigns driven by social discovery.
Atmosfy is actively expanding its global partner network to make millions of experiences instantly bookable on the platform while also offering rewards through the All-Access Pass to the platform's engaged audience. With marquee partners like Capital One, Expedia, and Tock already on board, Atmosfy is shaping the next generation of travel and commerce and delivering unmatched savings, reach, and loyalty.
To explore partnership opportunities, visit atmosfy.io or reach out to [email protected].
About Atmosfy
Atmosfy is the leading video discovery platform for Gen Z travel, dining, and experiences, spanning over 250 million discoveries across 10,000 cities and 150 countries. The company is backed by venture firms including Redpoint Ventures, Village Global, Canaan Partners, Industry Ventures, Streamlined Ventures, Palm Tree Crew, and others. Learn more at atmosfy.io.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250604270684/en/
CONTACT: Press Contact:
Cassie Lawrence
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: GENERATION Z AIR AUDIO/VIDEO TRANSPORT OTHER ENTERTAINMENT SOFTWARE BANKING CONSUMER PROFESSIONAL SERVICES TECHNOLOGY ENTERTAINMENT VACATION OTHER TRAVEL GENERAL ENTERTAINMENT APPS/APPLICATIONS LODGING DESTINATIONS TRAVEL
SOURCE: Atmosfy
Copyright Business Wire 2025.
PUB: 06/04/2025 08:03 AM/DISC: 06/04/2025 08:02 AM
http://www.businesswire.com/news/home/20250604270684/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Young Investor Demand for Alternative Assets Is Reshaping Wall Street's Playbook
Wall Street has a new favorite investor. They're young, they're affluent and they're skeptical that traditional markets can deliver wealth over the long haul. Shaped by financial crises and fueled by tech optimism, this well-heeled class of Millennials and Gen Z are moving their money into the buzzy world of alternative assets. Think pre-IPO unicorns, real estate, crypto, collectibles, and more. From private banks to fintech platforms, the financial industry is rushing to keep up. Firms like Forge Global Holdings Inc. have lowered their minimum investment thresholds, pitching private-market access as aspirational — and attainable.
Business Wire
an hour ago
- Business Wire
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that it will present data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) in an oral presentation at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 25-27, 2025, in Anaheim, California. SAPPHIRE evaluated the safety and efficacy of apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with SMA who are receiving SMN-targeted treatments. Scholar Rock previously shared positive topline data from the trial in October 2024 and announced in March 2025 that the U.S. FDA accepted its BLA for apitegromab. The application has a priority review designation, and the FDA has assigned a PDUFA target action date of September 22, 2025. Details of the oral presentation are as follows: Title: Efficacy and Safety of Apitegromab in Individuals with Type 2 and Type 3 Spinal Muscular Atrophy Evaluated in the Phase 3 SAPPHIRE Trial Presentation type: Oral presentation Presenter: Basil T. Darras, M.D., Associate Neurologist-in-Chief, Boston Children's Hospital and Professor of Neurology, Harvard Medical School Location: Sequoia Ballroom, Disney's Grand Californian Hotel Date and time: Friday, June 27, 11:20 a.m. PDT Scholar Rock will also present a poster on a systematic literature review of characterization of the longer-term effectiveness of SMN-targeted therapies for SMA. The details of that poster presentation are as follows: Title: Characterization of the Longer-Term Effectiveness of SMN-Targeted Treatments for Spinal Muscular Atrophy: A Systematic Literature Review Presentation type: Poster presentation Presenter: Jena M. Krueger, M.D., Helen DeVos Children's Hospital Grand Rapids, Michigan Location: Frontier Tower Magic Kingdom Rooms 2 & 3, Disneyland Hotel Date and time: Wednesday, June 25, 4:30-6:30 p.m. PDT The presentations will be made available in the Publications & Posters section of Scholar Rock's website following the conference. For conference information, visit About Apitegromab Apitegromab is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is the first muscle-targeted treatment candidate in spinal muscular atrophy (SMA) to demonstrate clinical success in a pivotal phase 3 clinical trial. Additionally, in the EMBRAZE Phase 2 proof-of-concept trial in obesity, patients receiving apitegromab dosed at 10mg/kg with tirzepatide over 24 weeks showed a statistically significant preservation of lean mass relative to tirzepatide alone. Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. Apitegromab has not been approved for any use by the FDA or any other regulatory agency. About the Phase 3 SAPPHIRE Trial SAPPHIRE was a randomized, double-blind, placebo-controlled Phase 3 clinical trial that evaluated the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 SMA who were receiving current standard of care (either nusinersen or risdiplam). SAPPHIRE enrolled 156 patients aged 2-12 years old in the main efficacy population. These patients were randomized 1:1:1 to receive either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo by intravenous (IV) infusion every 4 weeks for 12 months. An exploratory population including 32 patients aged 13-21 years old was also evaluated. These patients were randomized 2:1 to receive either apitegromab 20 mg/kg or placebo every 4 weeks for 12 months. The SAPPHIRE trial met its primary endpoint for the main efficacy population with a statistically significant 1.8-point improvement (p=0.0192) based on apitegromab combined dose (10 mg/kg and 20 mg/kg) and standard of care (SOC) versus placebo and SOC as measured by the Hammersmith Functional Motor Scale-Expanded at week 52 (additional details in the topline data release). About SMA Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease that afflicts an estimated 30,000 to 35,000 people in the United States and Europe. The disease is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk, and progressive muscle weakness. While there has been progress in the development of therapeutics that address the loss of motor neurons, there continues to be a high unmet need for therapies that directly address the progressive muscle weakness that leads to loss of motor function in SMA. About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily, the company is named for the visual resemblance of a scholar rock to protein structures. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at and follow @ScholarRock and on LinkedIn. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, progress and plans for apitegromab. The use of words such as 'may,' 'might,' 'could,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether the results from the Phase 3 clinical trial of apitegromab, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates, and may not be sufficient for regulatory approval; Scholar Rock's ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; the data generated from Scholar Rock's nonclinical studies and clinical trials; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, supply for apitegromab; and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances; its ability to obtain regulatory approval of apitegromab; and the anticipated commercial launch in the United States of apitegromab in the fourth quarter of 2025 and new business initiatives; as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
Business Wire
an hour ago
- Business Wire
Wiley Appoints Craig Albright as Executive Vice President and Chief Financial Officer
BUSINESS WIRE)--Wiley (NYSE: WLY), one of the world's largest publishers and a global leader in research and education, today announced the appointment of Craig Albright as executive vice president and chief financial officer, effective June 26, 2025. Chris Caridi, who has led Wiley's finance organization as interim chief financial officer, will continue with the role of senior vice president, chief accounting officer and finance transformation leader. Albright joins Wiley with over 30 years of global leadership expertise in finance, strategy, and consulting roles. He recently served as CFO, Americas and Global Cash Center Lead at Xerox, where he oversaw multiple business units with annual sales ranging from $100 million to $2 billion, drove portfolio decisions, delivered significant cost savings, and instituted programs to improve cash conversion. Prior to that, he served as CFO, Commercial Excellence of Xerox overseeing strategic finance activities for three product divisions, including reporting, performance management, FP&A and capital allocation. He developed an organic growth program that identified strategic opportunities and performance indicators, resulting in $300 million in new revenue. In addition, Albright has successfully led finance organizations through global economic crises and disruptions while driving organic and inorganic growth and consolidating enterprise systems. Wiley recently reported its Fiscal 2025 earnings, where it delivered growth in all key metrics, including revenue, margins, and free cash flow. 'Craig joins Wiley at an exciting time for the Company. We are meeting and exceeding our financial commitments, driving growth in our core business while delivering material margin expansion, and capitalizing on emerging market opportunities in the corporate sector through AI licensing, data analytics, and knowledge services. Craig's exceptional track record of driving high-quality growth globally through disciplined investment and innovation, cost synergies, and operating efficiency lines up perfectly with our strategic objectives,' said Matthew Kissner, president and CEO of Wiley. 'I am very impressed with Craig's financial acumen, resiliency and determination, as evidenced by his extensive roles throughout multiple leadership changes at Xerox. I look forward to partnering with Craig as we generate significant value for our customers, partners, and shareholders.' 'Joining Wiley represents an incredible opportunity to further position the Company for the AI age,' said Craig Albright, incoming executive vice president and chief financial officer. 'The Company's strong core business, coupled with its clear strategic priorities, creates multiple pathways for value creation. I'm eager to work with Matt, the talented Finance team, and all my new colleagues to build on the momentum that is driving margin and cash flow expansion, continuing to build core business momentum, and capitalizing on emerging opportunities for Wiley's high-quality content, data, and knowledge services.' 'On behalf of the Board, the Executive Leadership Team, and all our colleagues, I want to express my deep gratitude to Chris Caridi for his leadership and to our entire Finance team for their resilience, focus, and strong performance through this transition,' added Kissner. About Wiley Wiley (NYSE: WLY) is one of the world's largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We empower knowledge-seekers to transform today's biggest obstacles into tomorrow's brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Follow us on Facebook, Twitter, LinkedIn and Instagram.
